 National Cancer Institute (U.S.)
"National Cancer Institute (U.S.)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
| Descriptor ID |
D054547
|
| MeSH Number(s) |
I01.409.418.750.600.650.496.150 N03.540.052.750.150 N03.540.348.500.500.600.650.496.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "National Cancer Institute (U.S.)".
Below are MeSH descriptors whose meaning is more specific than "National Cancer Institute (U.S.)".
This graph shows the total number of publications written about "National Cancer Institute (U.S.)" by people in this website by year, and whether "National Cancer Institute (U.S.)" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 2 | 0 | 2 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 1 | 3 | 4 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 2 | 2 | | 2020 | 0 | 4 | 4 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 3 | 3 | | 2025 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "National Cancer Institute (U.S.)" by people in Profiles.
-
Villalobos A, Lipman PD, Beebe-Dimmer J, Borrayo EA, Briant KJ, Bruegl A, Dee C, Chavez S, Drake B, Johnson SS, Kikuchi K, Leeman J, Lowery J, Mendoza JA, Parker M, Purvis L, Wells Sittig K, Thompson HS, Wangen M, Wheeler SB. Synergies, partnership outcomes, and lessons learned: a qualitative evaluation of cancer center-coalition engagement. JNCI Cancer Spectr. 2025 Apr 30; 9(3).
-
Goff SL, Rosenberg SA. Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCI. J Immunother Cancer. 2025 Apr 09; 13(4).
-
Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA. Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. JCO Precis Oncol. 2025 Mar; 9:e2400489.
-
Yabroff KR, Boehm AL, Nogueira LM, Sherman M, Bradley CJ, Shih YT, Keating NL, Gomez SL, Banegas MP, Ambs S, Hershman DL, Yu JB, Riaz N, Stockler MR, Chen RC, Franco EL. An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. J Natl Cancer Inst. 2023 10 09; 115(10):1115-1120.
-
Yabroff KR, Boehm AL, Nogueira LM, Sherman M, Bradley CJ, Shih YT, Keating NL, Gomez SL, Banegas MP, Ambs S, Hershman DL, Yu JB, Riaz N, Stockler MR, Chen RC, Franco EL. An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. JNCI Cancer Spectr. 2023 08 31; 7(5).
-
Oh AY, Emmons KM, Brownson RC, Glasgow RE, Foley KL, Lewis CC, Schnoll R, Huguet N, Caplon A, Chambers DA. Speeding implementation in cancer: The National Cancer Institute's Implementation Science Centers in Cancer Control. J Natl Cancer Inst. 2023 02 08; 115(2):131-138.
-
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 11 01; 128(21):3775-3783.
-
Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 02; 6:e2100424.
-
Burris JL, Borger TN, Shelton BJ, Darville AK, Studts JL, Valentino J, Blair C, Davis DB, Scales J. Tobacco Use and Tobacco Treatment Referral Response of Patients With Cancer: Implementation Outcomes at a National Cancer Institute-Designated Cancer Center. JCO Oncol Pract. 2022 02; 18(2):e261-e270.
-
Kirby J, Prior F, Petrick N, Hadjiski L, Farahani K, Drukker K, Kalpathy-Cramer J, Glide-Hurst C, El Naqa I. Introduction to special issue on datasets hosted in The Cancer Imaging Archive (TCIA). Med Phys. 2020 Dec; 47(12):6026-6028.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|